Kaken Pharmaceutical Co., Ltd. ("Kaken", head office Bunkyo-ku, Tokyo) announced today that Almirall S.A. ("Almirall", head office Barcelona, Spain) has filed for the regulatory submission for efinaconazole, a novel triazole anti-fungal compound discovered by Kaken, in Germany and Italy under the European decentralised procedure. Kaken granted the exclusive right for development and commercialization of efinaconazole in Europe to Almirall in July, 2021.

Efinaconazole is contained in Clenafin® / Jublia® ("Product"), topical formulation drug for onychomycosis, as its active ingredient. Since efinaconazole has low binding affinity with keratin, the main component of nails, the Product has superior nail-penetrating properties.

Under the trade name of Clenafin®, the Product has been marketed in Japan since 2014. The Product also has been launched under the trade name of Jublia® in the United States, Canada, Korea, Taiwan, Hong Kong and Macau by Kaken's partner companies.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit almirall.com

Back to list

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Kaken Pharmaceutical Co. Ltd. published this content on 30 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2022 00:51:02 UTC.